Form 4: Acadia Pharmaceuticals Executive James Kihara Reports Stock Transactions
SEC Form 4 Filing
Principal Accounting Officer James Kihara reports acquisition and disposal of Acadia Pharmaceuticals stock and stock options.
Summary
- James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On March 25, 2025, Kihara acquired 2,142 shares of common stock through the vesting of restricted stock units and disposed of 1,095 shares at $17.05 on March 26, 2025.
- These sales were mandatory to cover withholding taxes related to the vesting of restricted stock units.
- Kihara also acquired 22,152 stock options on March 24, 2025, which vest over time.
- Following these transactions, Kihara directly owns 21,275 shares of common stock, 22,152 stock options, and 6,426 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports required insider trading activity.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives.
Key Dates
| Date | Description |
|---|---|
| 03/24/2025 | Date of earliest transaction; Stock options acquired; Restricted stock units acquired |
| 03/25/2025 | Restricted stock units vest and convert to common stock |
| 03/26/2025 | Shares disposed of to cover withholding taxes; Form 4 filing date |
| 03/23/2035 | Expiration date of stock options |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Acadia Pharmaceuticals, Kihara, Stock Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.